These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 17412550)

  • 1. Therapeutic adherence to bisphosphonates.
    Payer J; Killinger Z; Ivana Sulková ; Celec P
    Biomed Pharmacother; 2007 May; 61(4):191-3. PubMed ID: 17412550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferences of patients receiving bisphosphonates--how to influence the therapeutic adherence.
    Payer J; Killinger Z; Sulková I; Celec P
    Biomed Pharmacother; 2008 Feb; 62(2):122-4. PubMed ID: 17888616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compliance with treatment in osteoporosis patients--an ongoing problem.
    Sambrook P
    Aust Fam Physician; 2006 Mar; 35(3):135-7. PubMed ID: 16525527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adherence to treatment in osteoporosis influence on efficiency].
    Reginster JY; Rabenda V
    Rev Med Suisse; 2005 Oct; 1(35):2278-81. PubMed ID: 16268451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
    Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
    J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors contributing to compliance with osteoporosis medication.
    Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S; Olson M; van Staa TP
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis.
    Epstein S; Zaidi M
    Bone; 2005 Oct; 37(4):433-40. PubMed ID: 16046205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA; Schousboe JT; Cline RR; Weiss TW
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of persistence with weekly bisphosphonates in patients with osteoporosis.
    Jones TJ; Petrella RJ; Crilly R
    J Rheumatol; 2008 Sep; 35(9):1865-73. PubMed ID: 18709688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills.
    Weiss TW; Henderson SC; McHorney CA; Cramer JA
    Curr Med Res Opin; 2007 Sep; 23(9):2193-203. PubMed ID: 17686228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective.
    Boonen S
    Curr Med Res Opin; 2009 Oct; 25(10):2335-41. PubMed ID: 19650755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models.
    Zambon A; Baio G; Mazzaglia G; Merlino L; Corrao G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):260-9. PubMed ID: 18240162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of which anti-osteoporosis therapeutic regimen would improve compliance in a population of elderly adults.
    Richards JB; Cherkas LF; Spector TD
    Curr Med Res Opin; 2007 Feb; 23(2):293-9. PubMed ID: 17288683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA.
    Kishimoto H; Maehara M
    Arch Osteoporos; 2015; 10():231. PubMed ID: 26297076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.